1. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

LAG3 CD8 T cells

" in MedChemExpress (MCE) Product Catalog:

2

Inhibitors & Agonists

1

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-144088

    HPK1-IN-22

    MAP4K Inflammation/Immunology Cancer
    ZYF0033 is effective in inhibiting hematopoietic progenitor cells HPK1, basically inhibiting MBP protein oxidation IC50 10 nM . ZYF0033 promotes anti-cancer immune response, lowers SLP76 (acid 376) oxidation. ZYF0033 Suppression 4T-1 Small mouse model with the same underlying cause, medium bulge growth length expansion DC, NK 细细和 CD107a + CD8 + T Cells, PD-1 +CD8 + T Cells, TIM-3 +CD8 + T Cells LAG3< sup>+CD8 + T Cellular immersion decreases.
    ZYF0033
  • HY-P99933

    IMP321; LAG-3Ig

    LAG-3 Cancer
    Eftilagimod alfa (IMP321) is a recombinant LAG-3Ig fusion protein that binds to MHC class II. Eftilagimod alfa mediates antigen-presenting cell (APC) activation followed by CD8 T-cell activation. Eftilagimod alfa can be used for metastatic melanoma and metastatic breast carcinoma research .
    Eftilagimod alfa

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: